314 related articles for article (PubMed ID: 20104229)
1. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
[TBL] [Abstract][Full Text] [Related]
2. PTEN genomic deletion is an early event associated with ERG gene rearrangements in prostate cancer.
Bismar TA; Yoshimoto M; Vollmer RT; Duan Q; Firszt M; Corcos J; Squire JA
BJU Int; 2011 Feb; 107(3):477-85. PubMed ID: 20590547
[TBL] [Abstract][Full Text] [Related]
3. ERG rearrangement is associated with prostate cancer-related death in Chinese prostate cancer patients.
Qi M; Yang X; Zhang F; Lin T; Sun X; Li Y; Yuan H; Ren Y; Zhang J; Qin X; Han B
PLoS One; 2014; 9(2):e84959. PubMed ID: 24516518
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
[TBL] [Abstract][Full Text] [Related]
5. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
[TBL] [Abstract][Full Text] [Related]
6. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients.
Baena E; Shao Z; Linn DE; Glass K; Hamblen MJ; Fujiwara Y; Kim J; Nguyen M; Zhang X; Godinho FJ; Bronson RT; Mucci LA; Loda M; Yuan GC; Orkin SH; Li Z
Genes Dev; 2013 Mar; 27(6):683-98. PubMed ID: 23512661
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
[TBL] [Abstract][Full Text] [Related]
9. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
[TBL] [Abstract][Full Text] [Related]
10. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer.
Reid AH; Attard G; Brewer D; Miranda S; Riisnaes R; Clark J; Hylands L; Merson S; Vergis R; Jameson C; Høyer S; Sørenson KD; Borre M; Jones C; de Bono JS; Cooper CS
Mod Pathol; 2012 Jun; 25(6):902-10. PubMed ID: 22460813
[TBL] [Abstract][Full Text] [Related]
11. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
[TBL] [Abstract][Full Text] [Related]
12. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Attard G; Clark J; Ambroisine L; Fisher G; Kovacs G; Flohr P; Berney D; Foster CS; Fletcher A; Gerald WL; Moller H; Reuter V; De Bono JS; Scardino P; Cuzick J; Cooper CS;
Oncogene; 2008 Jan; 27(3):253-63. PubMed ID: 17637754
[TBL] [Abstract][Full Text] [Related]
13. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
14. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
[TBL] [Abstract][Full Text] [Related]
15. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract][Full Text] [Related]
16. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
[TBL] [Abstract][Full Text] [Related]
17. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer.
Paulo P; Barros-Silva JD; Ribeiro FR; Ramalho-Carvalho J; Jerónimo C; Henrique R; Lind GE; Skotheim RI; Lothe RA; Teixeira MR
Genes Chromosomes Cancer; 2012 Mar; 51(3):240-9. PubMed ID: 22081504
[TBL] [Abstract][Full Text] [Related]
18. Interaction of the Androgen Receptor, ETV1, and PTEN Pathways in Mouse Prostate Varies with Pathological Stage and Predicts Cancer Progression.
Higgins J; Brogley M; Palanisamy N; Mehra R; Ittmann MM; Li JZ; Tomlins SA; Robins DM
Horm Cancer; 2015 Jun; 6(2-3):67-86. PubMed ID: 25631336
[TBL] [Abstract][Full Text] [Related]
19. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
[TBL] [Abstract][Full Text] [Related]
20. Complex patterns of ETS gene alteration arise during cancer development in the human prostate.
Clark J; Attard G; Jhavar S; Flohr P; Reid A; De-Bono J; Eeles R; Scardino P; Cuzick J; Fisher G; Parker MD; Foster CS; Berney D; Kovacs G; Cooper CS
Oncogene; 2008 Mar; 27(14):1993-2003. PubMed ID: 17922029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
